Anbogen Therapeutics, Inc.
Update：2025/12/24
Industries
Main Industry
Biotechnology
Main Product/Service
Anbogen’s drug pipeline features two lead small‑molecule candidates: “ABT‑101,” a tyrosine kinase inhibitor targeting HER2 exon20 insertion mutations in non‑small cell lung cancer; and “ABT‑301,” an HDAC1/2/3 inhibitor designed for combination therapy wit
Founded Year
2019
Unified Business No.
82833776
Status
Active
Number of Employees
0
Total Paid-in
Capital
935,133,597 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Exclusive content for members
Members-only content. Please log in to access.
Introduction
Anbogen Therapeutics, Inc. is a Taipei‑based clinical‑stage biotech company focused on developing precision oncology drugs, with a mission to transform outcomes for cancer patients through innovative therapies.
